Combining Biomarkers and Electronic Risk Scores to Predict AKI in Hospitalized Patients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Chicago
About this trial
The study's objective is to evaluate the additive value of renal biomarkers (from blood and urine) for identifying individuals at high risk for severe acute kidney injury (AKI) above that of a novel natural language processing (NLP)-based AKI risk algorithm. The risk algorithm is based on electronic health records (EHR) data (labs, vitals, clinical notes, and test reports). Patients will enroll at the University of Chicago Medical Center and the University of Wisconsin Hospital, where the risk score will run in real time. The risk score will identify those patients with the highest risk for the future development of Stage 2 AKI and collect blood and urine for biomarker measurement over the subsequent 3 days.
Eligibility criteria
Qualifiers
Age ≥ 18 years
E-STOP AKI 2.0 score in the top 10% of risk (historically from all hospitalized patients) within the last 12 hours. (First time across this 10% risk threshold during this hospital stay).
Admitted to an inpatient ward, intermediate, or ICU care at the University of Chicago Medical Center (UCMC) or University of Wisconsin Health (UWHealth). (No Emergency Department patients)
Patient or their legally authorized representative must be able to read, speak, and understand English, for the purposes of consenting. Otherwise, inclusion in this protocol will be done without regard to race, ethnic origin or gender
Disqualifiers
Voluntary refusal or missing written consent of the patient / legal representative.
Patients with a known history of end-stage renal disease on dialysis (including renal transplantation).
Patients without a measured serum creatinine value during their inpatient stay.
Patients with a creatinine >4.0 mg/dl at the time of admission or available in the EHR from the last 6 months
Trial design
Treatments tested in this trial
- ESTOP - AKI 2.0
Treatment groups
800 Participants
are divided into 1 treatment groupSponsors and collaborators
University of Chicago
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator
University of Wisconsin, Madison
Collaborator
Source ClinicalTrials.gov